Lv4
506 积分 2023-08-23 加入
为高质量的临床试验而奋斗，为改变临床实践而奋斗，为医药进步和患者健康而奋斗~
High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients
6小时前
待确认
Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy
6小时前
待确认
Opportunities and challenges for targeting HPK1 in cancer immunotherapy
9小时前
已完结
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
21天前
已完结
Nutritional management of gastric cancer
5个月前
已完结
A systematic examination of anti-drug antibody titer estimation: Applied recommendations
8个月前
已完结
A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies
11个月前
已完结
An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
1年前
已完结
An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
1年前
已完结
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective
1年前
已完结
皖公网安备34019202002308
